Evidence map›Paper›PMID 26255301›Full record

SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2016

Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials.

Wei Zhang, Xue-Yan Chen, Su-Wen Su, Qing-Zhong Jia, Tao Ding, Zhong-Ning Zhu, Tong Zhang

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 6 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 6 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Wei ZhangCapital Medical University School of Rehabilitation Medicine, China Rehabilitation Research Center, 10, Jiaomenbei Road, FengTai District, Beijing, 100068, China.
Xue-Yan ChenDepartment of Pharmacology, Hebei Medical University, 361, Zhongshan East Road, Shijiazhuang, 050017, China.
Su-Wen SuDepartment of Pharmacology, Hebei Medical University, 361, Zhongshan East Road, Shijiazhuang, 050017, China.
Qing-Zhong JiaDepartment of Pharmacology, Hebei Medical University, 361, Zhongshan East Road, Shijiazhuang, 050017, China.
Tao DingDepartment of Pathology, School of Basic Medicine, Hebei University of Chinese Medicine, 3, Xingyuan Road, Luquan, Shijiazhuang, 050200, China.
Zhong-Ning ZhuDepartment of Pharmacology, Hebei Medical University, 361, Zhongshan East Road, Shijiazhuang, 050017, China. zzn1970@hotmail.com.
Tong ZhangCapital Medical University School of Rehabilitation Medicine, China Rehabilitation Research Center, 10, Jiaomenbei Road, FengTai District, Beijing, 100068, China. zt61611@sohu.com.
Hebei Medical University · CNChina Rehabilitation Research Center · CNHebei University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this work is to investigate the efficacy of exogenous melatonin in the treatment of sleep disorders in patients with neurodegenerative disease. We searched Pubmed, the Cochrane Library, and ClinicalTrials.gov, from inception to July 2015. We included randomized clinical trials (RCTs) that compared melatonin with placebo and that had the primary aim of improving sleep in people with neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). We pooled data with the weighted mean difference in sleep outcomes. To assess heterogeneity in results of individual studies, we used Cochran's Q statistic and the I (2) statistic. 9 RCTs were included in this research. We found that the treatment with exogenous melatonin has positive effects on sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI) in PD patients (MD: 4.20, 95 % CI: 0.92-7.48; P = 0.01), and by changes in PSQI component 4 in AD patients (MD: 0.67, 95 % CI: 0.04-1.30; P = 0.04), but not on objective sleep outcomes in both AD and PD patients. Treatment with melatonin effectively improved the clinical and neurophysiological aspects of rapid eye movement (REM) sleep behavior disorder (RBD), especially elderly individuals with underlying neurodegenerative disorders. This meta-analysis provided some evidence that melatonin improves sleep quality in patients with AD and PD, and melatonin can be considered as a possible sole or add-on therapy in neurodegenerative disorders patients with RBD.

Indexed as

HumansHypnotics and SedativesMelatoninNeurodegenerative DiseasesRandomized Controlled Trials as TopicSleep Wake DisordersHypnotics and SedativesMelatoninAlzheimer diseaseMelatoninNeurodegenerative diseasesParkinson diseaseREM sleep behavior disorderSleep

Identifiers

PMID26255301
OpenAlexW1054347517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.